in the pathogenesis of erythropoietin-induced hypertension, and for endothelial cell damage in patients with chronic renal failure, has emerged and appears to be of major concern. We, therefore, investigated the effect of recombinant human erythropoietin (rHuEP0) therapy on endothelium-derived hormones in predialysis patients with progressive renal anemia.
he introduction of recombinant human tion.1-3 Attention has also been focused on the effect erythropoietin (rHuEP0) for the treatment of rHuEP0 therapy on blood pressure.4,5 However, it of renal anemia has renewed interest in the seems important to analyze the effect of rHuEP0 not effect of correcting anemia on renal funconly on the kidneys ar,d blood pressure but also on other systems, including endothelium. Recent studies have shown the possible pathophysiological involvement of endothelium-derived hormones in the course of progression and maintenance of erythropoietin-induced hypertension and renal diseases.6-'0 Endothelium is wide!y distributed. It is found in the luminal surface of systemic vascular beds, intrarenal vascular vessels a?rd glomerular capillary loop, contributing to a variety of regulatory systems in the kidney. Endothelial cells produce regional hormones such as thrombomodulin and endothelin. Physiologically, the former plays a pivotal role in the anticoagulant pathway, while the latter is involved in the regulation of peripheral vascular resistance. An elevated circulating soluble Tm has been found in patients with impaired renal function *I; Tm levels are positively correlated with the severity of the impaired renal function. Abnormally elevated ET-l levels have been found in patients with chronic renal failure.'o,'z Since Tm and ET-l are released from endothelial cells when they are damaged, elevated circulating Tm and ET-l levels in renal diseases are considered to arise from damage to vascular endothelial cells rather than reduced urinary excretion capacity."-'* In view of these observations, it seems reasonable that an elevation of circulating Tm and ET-1 reflects the severity of endothelial cell damage, and that it can be regarded as a useful indicator for monitoring vascular endothelial cell damage.
Chronic renal failure patients at the predialysis stage have progressive anemia and benefit from rHuEP0 therapy. 15-17 However, the correction of their anemia may have both beneficial or deleterious effects on renal function and blood pressure.'"," In this regard, the issue of whether the correction of anemia by rHuEP0 influences endothelial cell function is of major concern. Assuming that an elevation. of circulating Tm and ET-1 could reflect endothelial cell damage and/or dysfunction, the present study investigated the effect of rHuEP0 therapy on the endothelium derived hormones, Tm and ET-l, in predialysis patients.
METHODS
Patients Enrolled in this study were 20 outpatients (10 women, 10 men, average age 57, range 32 to 70) -with chronic renal failure at the pre-dialysis stage. The underlying causative renal diseases were chronic glomerulonephritis in eight, diabetic nephropathy in eight, ne@rosclerosis in two, but were unknown in two. We used a plasma creatinine concerttratlon of 4 to 5 mg / dL as an inclusion criterion. The mean Ccr at entry was 15 2 4 mL /min / 1.73 m2, and the hematocrit less than 30%. The cause of anemia in all patients was secondary to chronic renal failure. Nine patients had hypertension, which was treated with Ca antagonists, &blockers, ablockers and angiotensin converting enzyme (ACE) inhibitors. All patients were placed on a strict diet for predialysis chronic renal failure that consists of total calorie intake of 3.2 cal/ kg/ day, protein of 0.6 g/kg / day, NaCl of 5 g ,' day and K of 1.0 g/day. The dietary and medication regimens were kept constant for at least 2 months prior to the study and attempts were made to keep them so throughout the study period. Four patients (two men and two women) dropped out of the study after it started, due to their inability to receive periodical rHuEI'0 injections. Ali patients gave informed consent before the Ftudy.
Methods
Six thousand units of rHuEP0 (p-erythropoietin, Chugai Pharmaceutical Co. Ltd., Japan) were injected into the predialysis patients intravenously once a week on an outpatient basis over 16 weeks. In order to maintain serum iron and ferritin concentrations at adequate level, iron was given intraveneously as deemed appropriate, the target level for serum iron was set at 100 pg/dL and for ferritin at 100 ng/mL. Blood samples were taken regularly every 4 weeks to measure CBC, serum iron concentration, TIBC, UIBC, ferritin, blood urea nitrogen (BLW) concentration, and creatinine concentration.
Measurements of Blood Parameters
Serum creatinine concentration (Cr) and blood urea nitrogen concentratiwl (BUN) were measured using an autoanalyzer. Various blood hormone measurements, including plasma renin activity (PRA), or-human atria1 natriuretic peptide (h-ANI'), epinephrine (ADN), norepinephrine (NADN), dopamine concentration (DPN), serum thrombomodulin concentration (Tm) and plasma endothelin-1 concentration (ET-l) were performed at the beginning and end (16 weeks) of the treatment. To determine the norm& range of 'Tm and ET-l, blood samples were taken from 25 age-and sex-matched subjects (average age Ejq, ranging from 35 to 68, 15 men and 13 females) with normal renal function. The Tm in the normal subjects was 3.5 t 0.7 FU/mL and the ET-I 1.32 2 0.4 pg/mL. Tm was meastired by the or~Q.ep sandwich method of EIA. ET-l, PRA and h-AhT were measured by IUA. ADN, NADN and DPN were measured by HPLC.
Blood pressure and urinalysis
Blood pressure was determined every week in the outpatient clinic with patients in the sitting position. The mean of three consecutive blood pressure measurements was caleLated and used as the determined blood pressure value. Twenty-four-hour urine samples were collected by spontaneous micturition and used for the deterz~la-tion of Cr, Na and K concentrations, and Tm. Crca+tine clearances (Ccr) were calculated using the standard clearance formula C = LGr / P f where C is the clearance, LJ is the urinary creatinine concentration, and fi the daily urine volume), and expressed as milliliters per minute per 1.73 square meters of body surface. 
Statistical Analysis
All results are expressed as mean ? SD, unless otherwise indicated. Student f test procedures for paired samples or independent samples were used as appropriate for the statistical analysis. Differences were considered statistically significant at P less than .05. Figure 1 shows the Tm and ET-l levels of 16 predialysis patients and 28 normal subjects. The levels of Tm and ET-l in the predialysis patients are substantially greater than the respective xlalues of the normal subjects. Figure 2 shows the relationship between the endothelium derived hormones, Tm and ET-l, and Cr at the entry to the study. A positive correlation was found between Tm and Cr. No correlation was found between ET-1 and Cr. In addition, no correlation was found between systolic blood pressure and ET-l, and between diastolic blood pressure and ET-I (data not shown). Y=1.76zx+1.163 RO.61
RESULTS
1996-VOL. 9, NO. 5 Figure 3 shows the effect of rHuEP0 therapy on rena! anemia. The hematocrit (open circles) and hemoglobin concentration (closed circles) increased markedly in a stepwise fashion over a period of 16 weeks as a result of the rHuEP0 therapy in all of the predialysis patients enrolled. Figure 4 shows how Tm was affected by the rHuEP0 therapy. At the entry to the trial, Tm was 7.9 f 2.8 ng/ mL (n = 16), which was significantly higher than that in age-and sex-matched normal healthy subjects (3.5 -C 0.7 ng/mL (n = 28), P < ,001). After the treatment with rHuEP0, Tm was significantly decreased. Figure 4 shows how the serum Tm/ creatinine (Tm/ Cr) ratio changed. As for Tm, the Tm/Cr ratio was also significantly lower after the rHuEP0 therapy. Figure 5 shows how ET-1 was affected by the rHuEP0 therapy. T hrre i;'h< no change in t&s parameter. Table 1 shows the effect of rHuEP0 therapy for 16 weeks on various clinical parameters. Blood pressure, Ccr, BUN. Cr, PRA, h-ANP, ADN, NADN, DPN, urinary Tm concentration, total amount of Tm excretion and fractional Tm clearance (CTm/Ccr), urinary albumin concentration, and protein excretion remained unchanged throughout the study.
DISCUSSION
Tm is a glycoprotein located at the surface of endothelial cells. It is involved in anticoagulant pathways in which it intracellularly activates protein C. ET-1 is secreted from endothelial cells, and is a potent vasocon&ictor that constricts afferent and efferent arterioles in the kidney and lowers GFR and RBF. It acts on renal mesangial cells, reducing Kf and GFR. ET-l also stinulates cell growth, presumably contributing to the pathogenesis of renal diseases including glomerulonephritis.
Using these two endothelium derived hormones as marker:; for endothelial cell function, the present study showed that Tm and ET-l are substantially higher in predialysis patients than in healthy subjects, 
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- and that correcting anemia by rHuEP0 therapy low-derlying endothelial cell Lamage in some patients ered Tm in such patients, whereas renal function re-with renal diseases; and second, that Tm and ET-1 mained unchanged throughout the study period. One could be good Ldicators for endothelial cell damage, must be critical, however, of the assumption that these Also one must be aware of the fact that the changes hormones are proper indicators of endothelial cell in circulating Tm and ET-1 may not be due only to damage. An elevated circulating Tm has been found their release from endothelial cells, as renal function in 3 xrariety of renal diseases, including glomerulonephritis and lupus nephritis6-s In addition, circulating also affect the circulating levels of these hormones. Their levels could be determined on the basis that the Tm is positively correlated with the severity of the impaired renal function.' Elevated circulating ET-l lower the renal capacity became, the higher the Tm and ET-1 blood concentration would be. In the present levels have also been found in patients with advanced study, renal function, blood presswe, aild the total renal failure and this is positively correlated with the severity o i impaired renal fi?n~tion.'~-'~ Furthermore, amount of daily Tm excretion remained elzchanged throughout the study period. This evidence unequivoTm is present in the systemic circulation, and is increased b)' endothelial cell damage.6-8,'* These obsercally excludes the possibility that increased renal excretory capacity reduced the circulating Tm, making vations raise two possibilities: first, that there is un-it reasonable to suggest that this was due to an im- in circulating Tm could also be due to enhanced nonrenal elimination by the liver or, less likely, due to increased catabolism by kidney parenchyma. Taken together, our data strongly suggest the beneficiai effect of rHuEP0 therapy on endothelial cell dysfunction in predialysis chronic renal failure patients. An improved hematocrit may renew the endothelial ce!l environment by increasing its oxygen "upply. Direct evidences for rHuEP0 receptors in vascular endothelium and for rHuEFO-induced ET-I reIease from endothelium have emerged in both human and animal studies,"@= which partially explain the pathogenesis of so-called rHuEPO-induced hypertension. We found that the ET-I in predialysis patients was higher than that in the normal subjects, but this was not associated with the elevation of blood pressure. Further, rHuEP0 therapy did not influence ET-I, per se. The present study also confirms previous work showing no direct effect of rHuEP0 on circulating ET-1 levels.23 These findings suggest that the contribution of circulating ET-I in the regulation of blood pressure in predialysis patients is small.
There are risks of increased blood pressure in a considerable proportion of rHuEP0 treated patients, on oat E.sx?.'~~~** However, amelioration of renal anemia by rHuEP0 does not cause an increase in blood pressure. 25 This discrepancy could be explained by the fact that a rapid rise in Ht is associated with a rise in blood pressure. A rise in Ht is more than 0.6% / week in the former reports, and is less than that in the latter. The rate of increase in Ht in our patients is 0.51% /week, thus possibly resulting in no change ir. blood pressure. Little is known regarding the effect of rHuEP0 on blood pressme regu!ating hormones such as PRA, h-ANP and catecholamines.
Our results shows no changes in these parameters, along with no changes in blood pressure after the treablcnt with rHuEP0 (see Table 1 ). This is in accordance with the previous finding showing that rHuEP0 therapy does not affect PRA, angiotensin II, and noradrenaline concentration in patients with chronic renal failure." The absence of rHuEP0 effect on these parameters indicates that none of these substances are involved in the regulation of blood pressure during rHuEP0 therapy.
In summary, rHuEP0 therapy reverses abnormally elevated concentrations of the endothelial derived hormone, Tm, in predialysis patients with progressive anemia, suggesting the beneficial effect of rHuEP0 on endothelial dysfunction.
